Navigation Links
Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
Date:3/6/2008

Presented at Miami Breast Cancer Conference, study demonstrates BSGI is

both patient and cost effective.

NEWPORT NEWS, Va., March 6 /PRNewswire/ -- A recent study performed by Dr. Margaret Bertrand, Director of Breast Imaging at Solis Bertrand Breast Center in Greensboro, North Carolina demonstrated the significant value of Breast-Specific Gamma Imaging (BSGI) as an adjunctive procedure in breast diagnostics; specifically demonstrating BSGI to be a useful and cost effective procedure in the breast diagnostic work up. The study results were recently presented at the Miami Breast Cancer Conference.

Breast-Specific Gamma Imaging is a molecular breast imaging technique used for the early detection of breast cancer and in the differentiation of malignant and benign tumors. It relies on advanced gamma imaging technology and mammographic positioning to optimize results. For this study BSGI was conducted with a commercially available high-resolution gamma camera, the Dilon 6800.

Dr. Bertrand's study evaluated the clinical impact of BSGI as an adjunctive imaging modality in a comparative analysis with other imaging methods; using tissue biopsy as the gold standard. The facility conducted diagnostic workup, including BSGI, on 98 lesions consisting of 69 malignancies.

Because imaging was prescribed as necessary, not all modalities were employed for each case. Since all patients had both mammography and BSGI, these were established as the constants with US and MRI as variables. Seventy-five percent (64/75) of the lesions detected when BSGI was compared to MRI had concordant BSGI and MRI findings with 11 discrepancies. In 74 of the 75 lesions BSGI was conducted pre-biopsy, while MRI was conducted post-biopsy, therefore it is not certain if the MRI findings were positive due to biopsy or disease.

In addition, BSGI was False Negative (FN) in 3 patients and False Positive (FP) in 2, while MRI was FN for 1 patient and F
'/>"/>

SOURCE Dilon Technologies LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Finds Starion Instruments Tissue Welding Technology Safe and Effective in Parotidectomy Procedures
2. Thomson Healthcare Cancer Profiler Used in Study
3. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
4. Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone)
5. CMC, Moffitt Partner to Study Cancer
6. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
7. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
8. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
9. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
10. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
11. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... 2014 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... in New York on Wednesday, December ... Dr. Helen Torley , President and Chief Executive Officer, ... be webcast through the "Investors" section of Halozyme,s corporate website ... available for 90 days following the event. To access the ...
(Date:11/24/2014)... , Nov. 24, 2014  CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today that ... Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at ... City . A live webcast of the ... and will feature an overview of the company by ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3
... 2012   AMRI (NASDAQ: AMRI ), ... today the appointment of Ian Shott as President of ... and CEO. In this newly created role, Mr. Shott ... including the company,s site in Wales, United Kingdom, and ...
... 2012  Dr. Barry Edison announces that Barry Edison ... has the Pelleve® Wrinkle Reduction System, a revolutionary ... Dr. Edison uses Pelleve—an advanced radiofrequency technology—because the ... with noticeable results. "I am proud to now ...
Cached Medicine Technology:AMRI Announces President for AMRI Europe 2AMRI Announces President for AMRI Europe 3New Jersey Ophthamologist Now Offers Pelleve Wrinkle Reduction Treatment 2
(Date:11/26/2014)... The city of San Diego, California, ... forward with a plan to recycle wastewater – also ... Kleyne supports the San Diego plan as part of ... to Kleyne, by recycling water that San Diego already ... be greatly reduced. (Spagat, E, “San Diego looks to ...
(Date:11/26/2014)... 2014 For its December issue ... AIS Report on Blue Cross and Blue Shield Plans* ... the varied strategies the two Blues plans are implementing ... treatments for sleep apnea, ranging from brick-and-mortar retail stores ... linked to increased rates of a variety of serious ...
(Date:11/26/2014)... November 26, 2014 Loffler Companies has ... Week in Imaging, an online information and news publication ... is the sixth consecutive year Loffler has earned this ... , The Elite Dealer Awards honor the best and ... year’s Elite Dealer honorees were chosen for their innovative ...
(Date:11/26/2014)... With a redesign of the practice ... has enhanced the user experience and functionality of ... an online destination for orthopedic and sports medicine knowledge ... new and improved version of the website. The ... ever for current and prospective patients to find answers ...
(Date:11/26/2014)... 26, 2014 With Thousand Oaks cosmetic ... the prosthodontists at the Anacapa Dental Art Institute in Woodland ... can be daunting for some. , That is why they ... they offer. , “No dentist wants cost to come between ... teeth,” said Dr. Mamaly Reshad, partner in the Anacapa Dental ...
Breaking Medicine News(10 mins):Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5
... Novel HIV Drug to be Studied in Cell ... A $6 million, five-year federal grant to The ... to investigate a novel approach in treating HIV infection ... therapies for psychological and neurological effects in AIDS. ...
... to concerns that the human papillomavirus vaccine might promote ... found that the majority of respondents did not believe ... infections. The study, conducted by University of Illinois ... and in the November issue of the Journal ...
... utter words , THURSDAY, Oct. 15 (HealthDay News) -- ... how the human brain computes language. , "Two central ... study: one, the way in which higher cognitive processes ... two, the nature of what is perhaps the best-known ...
... to curtail secondhand smoke, experts say , , THURSDAY, Oct. ... really do work at reducing heart attacks from secondhand smoke, ... the risk of heart attack by up to 47 ... according to a report released Thursday by the U.S. Institute ...
... ... the life science, engineering and entertainment industries, announced today they have signed an intellectual ... incorporating Microsoft’s SenseCam technology worldwide. , ... Oxford UK (PRWeb UK) October 15, 2009 -- Vicon, developer of ...
... , NEW YORK, Oct. 15 The Nielsen Company ... CLIO Awards , one of the world,s most recognized international advertising ... "The Dr. Oz Show" and featured health expert ... Honorary CLIO Healthcare Award live at the first-ever CLIO Healthcare ...
Cached Medicine News:Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 3Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 4Health News:UIC study finds girls aware of HPV vaccine's benefits 2Health News:Brain Yields Up Clues to Language 2Health News:Smoking Bans Reduce Heart Attacks: Study 2Health News:Smoking Bans Reduce Heart Attacks: Study 3Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 2Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 3Health News:Dr. Oz, Host of 'The Dr. Oz Show,' to Accept Honorary CLIO Healthcare Award Live at Nielsen's First-Ever CLIO Healthcare Awards Mixer 2Health News:Dr. Oz, Host of 'The Dr. Oz Show,' to Accept Honorary CLIO Healthcare Award Live at Nielsen's First-Ever CLIO Healthcare Awards Mixer 3